Literature DB >> 18382142

Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children: standard pediatric versus a reduced-antigen content formulation.

Claudius U Meyer1, Pirmin Habermehl, Markus Knuf, Bernhard Hoet, Joanne Wolter, Fred Zepp.   

Abstract

Booster vaccination with a reduced-antigen-content dTpa, pediatric DTPa or adult Td vaccine in DTPa-primed children aged 4-6 years was evaluated. Immunogenicity and CMI was assessed one month and 3.5 years after vaccination. Symptoms were solicited for 15 days post-vaccination. There were no differences between groups in diphtheria or tetanus seroprotection or pertussis vaccine-response rates. Anti-diphtheria and anti-PRN concentrations were higher after DTPa, but groups differences reduced over time. Non-significant trends toward reduced reactogenicity of dTpa were observed. Many factors influence vaccine choice at preschool age. The dTpa vaccine was as immunogenic and possibly better tolerated than DTPa at this age.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 18382142     DOI: 10.4161/hv.4.3.5290

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  8 in total

1.  Differential T- and B-cell responses to pertussis in acellular vaccine-primed versus whole-cell vaccine-primed children 2 years after preschool acellular booster vaccination.

Authors:  Rose-Minke Schure; Lotte H Hendrikx; Lia G H de Rond; Kemal Oztürk; Elisabeth A M Sanders; Guy A M Berbers; Anne-Marie Buisman
Journal:  Clin Vaccine Immunol       Date:  2013-07-03

2.  Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Jennifer L Liang; Tejpratap Tiwari; Pedro Moro; Nancy E Messonnier; Arthur Reingold; Mark Sawyer; Thomas A Clark
Journal:  MMWR Recomm Rep       Date:  2018-04-27

3.  Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2 + 1 schedule in infancy.

Authors:  Giuseppe Ferrera; Mario Cuccia; Gabriele Mereu; Giancarlo Icardi; Gianni Bona; Susanna Esposito; Federico Marchetti; Marc Messier; Sherine Kuriyakose; Karin Hardt
Journal:  Hum Vaccin Immunother       Date:  2012-02-13       Impact factor: 3.452

4.  Booster vaccination: the role of reduced antigen content vaccines as a preschool booster.

Authors:  Giovanni Gabutti; Cecilia Trucchi; Michele Conversano; Giambattista Zivelonghi; Giorgio Zoppi
Journal:  Biomed Res Int       Date:  2014-02-11       Impact factor: 3.411

5.  Use of tetanus-diphtheria (Td) vaccine in children 4-7 years of age: World Health Organization consultation of experts.

Authors:  Shalini Desai; Heather M Scobie; Thomas Cherian; Tracey Goodman
Journal:  Vaccine       Date:  2020-01-23       Impact factor: 3.641

6.  ERRATA CORRIGE.

Authors: 
Journal:  J Prev Med Hyg       Date:  2021-04-29

Review 7.  Immunogenicity and antibody persistence of diphteria-tetanus-acellular pertussis vaccination in adolescents and adults: a systematic review of the literature showed different responses to the available vaccines.

Authors:  Raffaele Squeri; Cristina Genovese
Journal:  J Prev Med Hyg       Date:  2021-01-14

8.  Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study.

Authors:  Asmik Asatryan; Nadia Meyer; Michael Scherbakov; Victor Romanenko; Irina Osipova; Anna Galustyan; Olga Shamsheva; Tatiana Latysheva; Tatyana Myasnikova; Nathalie Baudson; Monique Dodet; Stebin Xavier; Lauriane Harrington; Anastasia Kuznetsova; Laura Campora; Peter Van den Steen
Journal:  Hum Vaccin Immunother       Date:  2020-08-26       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.